Business
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that two oral presentations and three poster presentations highlighting the breadth of its research pipeline and scientific leadership will be presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting, to be held April 17-22, 2026, in San Diego, California. The presentations will provide additional mechanistic validation of CBL-B, Aurora kinase A (AURKA) and mutant BRAF as therapeutic targets across multiple cancer indications and will highlight the potential of Nurix’s orally bioavailable degraders to effectively suppress the oncogenic activity of these proteins in preclinical models. Additionally, Gwenn Hansen, Ph.D., chief scientific officer of Nurix Therapeutics, has been selected to speak in an AACR Advances session on induced proximity pharmacology, including targeted protein degradation. AACR Advances sessions bring together leading scientific perspectives to provide a comprehensive view of recent developments, the current state of research, and emerging challenges in the field. Oral Presentation Details: Title: Designing Effective Degrader Therapeutics: What Early Clinical Experience Has Taught UsSpeaker: Gwenn Hansen, Ph.D., chief scientific officer, Nurix TherapeuticsSession type: Advances in Diagnostics and TherapeuticsSession title: Induced Proximity Pharmacology: Degraders and BeyondSession date and time: Wednesday, April 22, 2026, 10:15 a.m. – 11:45 a.m. PT Title: Discovery and characterization of CBL-B intramolecular glue inhibitors that increase T cell activation and suppress tumor growthPresenter: Fred Cohen, Ph.D. Session type: MinisymposiumSession category: ChemistrySession title: Targeted TherapiesSession date and time: Tuesday, April 21, 2026, 4:30 p.m. PTAbstract presentation #: 6733 Poster Presentation Details: Title: NRX-4972, a selective, oral, Aurora kinase A degrader, demonstrates increased efficacy in an SCLC tumor model, and greater in vitro synergy than an AURKA inhibitorPresenting author: Ryan Rountree, Ph.D.Session category: Targeted Protein Degradation and Induced ProximitySession title: Targeted Protein Degradation an...